Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Paroxysmal dysarthria-ataxia syndrome resolving after fingolimod treatment.
Analysis of Neurogenesis during Experimental Autoimmune Encephalomyelitis Reveals Pitfalls of Bioluminescence Imaging.
Correction: Selective Blockade of CD28-Mediated T Cell Costimulation Protects Rhesus Monkeys against Acute Fatal Experimental Autoimmune Encephalomyelitis.
Effectiveness of Group Versus Individual Yoga Exercises on Fatigue of Patients with Multiple Sclerosis.
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.
Diffusion basis spectrum imaging detects and distinguishes coexisting subclinical inflammation, demyelination and axonal injury in experimental autoimmune encephalomyelitis mice.
Time matters - Acute stress response and glucocorticoid sensitivity in early multiple sclerosis.
Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics.
The molecular physiology of the axo-myelinic synapse.
Expression of Signaling Molecules in Progressive Multifocal Leukoencephalopathy.
Extracellular Membrane Vesicles as Vehicles for Brain Cell-to-Cell Interactions in Physiological as well as Pathological Conditions.
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions.
PDGF is Required for Remyelination-Promoting IgM Stimulation of Oligodendrocyte Progenitor Cell Proliferation.
White matter disease: Aquaporin-4 antibody-positive patients may not always fulfil the clinical criteria for neuromyelitis optica.
Therapeutic options in neuromyelitis optica spectrum disorders.
Proof-of Concept that an Acute Trophic Factors Intervention After Spinal Cord Injury Provides an Adequate Niche for Neuroprotection, Recruitment of Nestin-Expressing Progenitors and Regeneration.
Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.
Unkind cytokines: current evidence for the potential role of cytokines in immune-mediated depression.
A role for Apolipoprotein A-I in the pathogenesis of multiple sclerosis.
Longitudinal assessment of clinically isolated syndrome with diffusion tensor imaging and volumetric MRI.
Eosinophilic CNS vasculitis can mimic demyelinating disease of the brain and spinal cord.
Estrogen treatment of experimental autoimmune encephalomyelitis requires E2 receptor positive B cells that upregulate PD-1 on CD4(+) Foxp3(+) Treg cells.
Generic quality of life burden of multiple sclerosis as compared to other debilitating chronic conditions.
Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
Combined central and peripheral demyelination.
Pages
« first
‹ previous
…
628
629
630
631
632
633
634
635
636
…
next ›
last »